Skip to main content

Advertisement

SpringerLink
Log in

Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients

  • Clinical trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

We have previously reported an association between ABCB1 C3435T polymorphism and docetaxel pharmacokinetics in breast cancer patients. We therefore investigated whether these parameters could account for variations in pathological response. Five ABCB1 polymorphisms including C3435T polymorphism were analyzed in breast cancer patients receiving neoadjuvant chemotherapy with doxorubicin and docetaxel (n = 101). Pathological response was assessed using the Sataloff classification. Pharmacokinetic analysis was performed for the first course of docetaxel (n = 84). No significant association was found between ABCB1 polymorphisms or docetaxel pharmacokinetics and pathological complete response. C3435T genotype was an independent predictive factor of good response in breast (response >50 %, i.e., Sataloff T-A and T-B): OR: 4.6 (95 % CI: 1.3–16.1), p = 0.015, for TT patients versus CT and CC patients. Area under the plasma concentration–time curve (AUC) of docetaxel was the only independent predictive factor of the total absence of response in breast (Sataloff T-D): OR: 14.3, (95 % CI: 1.7–118), p = 0.015, for AUC of docetaxel <3,500 μg h/L versus ≥3,500 μg h/L. These results suggest that C3435T polymorphism and docetaxel exposure are involved in the response to neoadjuvant chemotherapy in breast cancer patients and may be useful to optimize individualized therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bonadonna G, Veronesi U, Brambilla C et al (1990) Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82:1539–1545

    Article  PubMed  CAS  Google Scholar 

  2. van der Hage JA, van de Velde CJ, Julien JP et al (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19:4224–4237

    PubMed  Google Scholar 

  3. Kaufmann M, Morrow M, von Minckwitz G et al (2010) Locoregional treatment of primary breast cancer: consensus recommendations from an International Expert Panel. Cancer 116:1184–1191

    Article  PubMed  Google Scholar 

  4. Rouzier R, Mathieu MC, Sideris L et al (2004) Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors. Cancer 101:918–925

    Article  PubMed  Google Scholar 

  5. Rouzier R, Pusztai L, Delaloge S et al (2005) Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 23:8331–8339

    Article  PubMed  Google Scholar 

  6. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58

    Article  PubMed  CAS  Google Scholar 

  7. Schinkel AH (1997) The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 8:161–170

    Article  PubMed  CAS  Google Scholar 

  8. Fajac A, Gligorov J, Rezai K et al (2010) Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer 103:560–566

    Article  PubMed  CAS  Google Scholar 

  9. Sataloff DM, Mason BA, Prestipino AJ et al (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180:297–306

    PubMed  CAS  Google Scholar 

  10. Sauter G, Lee J, Bartlett JM et al (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27:1323–1333

    Article  PubMed  CAS  Google Scholar 

  11. Baille P, Bruno R, Schellens JH et al (1997) Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance. Clin Cancer Res 3:1535–1538

    PubMed  CAS  Google Scholar 

  12. Vergniol JC, Bruno R, Montay G et al (1992) Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J Chromatogr 582:273–278

    PubMed  CAS  Google Scholar 

  13. Bruno R, Hille D, Riva A et al (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187–196

    PubMed  CAS  Google Scholar 

  14. Beal SL, Sheiner LB (1998) NONMEM user’s guide. NONMEM project group, San Francisco

    Google Scholar 

  15. Kuerer HM, Newman LA, Smith TL et al (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460–469

    PubMed  CAS  Google Scholar 

  16. Harvey V, Mouridsen H, Semiglazov V et al (2006) Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24:4963–4970

    Article  PubMed  CAS  Google Scholar 

  17. Wang LG, Liu XM, Kreis W et al (1999) The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44:355–361

    Article  PubMed  CAS  Google Scholar 

  18. Goncalves A, Viret F, Ciccolini J et al (2003) Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors. Clin Cancer Res 9:102–108

    PubMed  CAS  Google Scholar 

  19. Seibel NL, Blaney SM, O’Brien M et al (1999) Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children’s Cancer Group trial. Clin Cancer Res 5:733–737

    PubMed  CAS  Google Scholar 

  20. Fellay J, Marzolini C, Meaden ER et al (2002) Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359:30–36

    Article  PubMed  CAS  Google Scholar 

  21. Hitzl M, Drescher S, van der Kuip H et al (2001) The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56 + natural killer cells. Pharmacogenetics 11:293–298

    Article  PubMed  CAS  Google Scholar 

  22. Hoffmeyer S, Burk O, von Richter O et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473–3478

    Article  PubMed  CAS  Google Scholar 

  23. Tanabe M, Ieiri I, Nagata N et al (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137–1143

    PubMed  CAS  Google Scholar 

  24. Vaclavikova R, Nordgard SH, Alnaes GI et al (2008) Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients. Pharmacogenet Genomics 18:263–273

    Article  PubMed  CAS  Google Scholar 

  25. Cizmarikova M, Wagnerova M, Schonova L et al (2010) MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J 10:62–69

    Article  PubMed  CAS  Google Scholar 

  26. George J, Dharanipragada K, Krishnamachari S et al (2009) A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer. Clin Breast Cancer 9:161–165

    Article  PubMed  CAS  Google Scholar 

  27. Kafka A, Sauer G, Jaeger C et al (2003) Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 22:1117–1121

    PubMed  CAS  Google Scholar 

  28. Kelly RJ, Draper D, Chen CC et al (2011) A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 17:569–580

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Assistance Publique-Hôpitaux de Paris and ACTT (Amis du Centre des Tumeurs de Tenon) association for financial support, URC-Est for help in the design of this study, and Jean-Pierre Lotz, Florent Soubrier and Serge Uzan for their constant support. This study was supported by Assistance Publique-Hôpitaux de Paris (Grant Number PHRC AOR03015) and ACTT (Amis du Centre des Tumeurs de Tenon) association.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Département de Santé Publique, hôpital Tenon, AP-HP, Inserm UMR S 707, Université Pierre et Marie Curie, 4 rue de la Chine, 75020, Paris, France

    Pierre Lévy

  2. Medical Oncology Department, Francilian Breast intergroup, hôpital Tenon, AP-HP, ER2 UPMC Université Pierre et Marie Curie, 4 rue de la Chine, Paris, 75020, France

    Joseph Gligorov, Frédéric Selle, Danielle Avenin, Karine Beerblock & Jean-Pierre Lotz

  3. Service d’Anatomo-Pathologie, hôpital Tenon, AP-HP, ER2 UPMC Université Pierre et Marie Curie, 4 rue de la Chine, 75020, Paris, France

    Martine Antoine

  4. Service de Pharmacologie, Centre René Huguenin, 35 rue Dailly, 92210, St-Cloud, France

    Keyvan Rezai & François Lokiec

  5. Service d’Oncologie, Intergroupe Francilien du sein, HEGP, AP-HP, 20 rue Leblanc, 75015, Paris, France

    Eric Lévy

  6. Service d’Oncologie, Hôpital Avicenne, AP-HP, 125 rue Stalingrad, 93000, Bobigny, France

    Pierre Saintigny

  7. Service d’Histologie-Biologie Tumorale, hôpital Tenon, AP-HP, ER2 UPMC Université Pierre et Marie Curie, 4 rue de la Chine, 75020, Paris, France

    Jean-François Bernaudin & Anne Fajac

Authors
  1. Pierre Lévy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph Gligorov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martine Antoine
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Keyvan Rezai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eric Lévy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Frédéric Selle
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pierre Saintigny
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. François Lokiec
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Danielle Avenin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Karine Beerblock
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jean-Pierre Lotz
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jean-François Bernaudin
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Anne Fajac
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph Gligorov.

Additional information

Joseph Gligorov & Pierre Lévy are the first co-authors. Anne Fajac, Pierre Lévy & Joseph Gligorov equally contributed to the study.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lévy, P., Gligorov, J., Antoine, M. et al. Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 139, 421–428 (2013). https://doi.org/10.1007/s10549-013-2545-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-013-2545-7

Keywords

Search

Navigation